CoChat

Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches—a narrative review

Open access

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Abstract

Objective: The aim of this review is addressing the mechanisms of asbestos carcinogenesis, including chronic inflammation and autophagy-mediated cell survival, and propose potential innovative therapeutic targets to prevent mesothelioma development or improve drug efficacy by reducing inflammation and autophagy. Background: Diffuse malignant pleural mesothelioma is an aggressive cancer predominantly related to chronic inflammation caused by asbestos exposure. Millions of individuals have been exposed to asbestos or to other carcinogenic mineral fibers occupationally or environmentally, resulting in an increased risk of developing mesothelioma. Overall patient survival rates are notably low (about 8–14 months from the time of diagnosis) and mesothelioma is resistant to existing therapies. Additionally, individuals carrying inactivating germline mutations in the BRCA-associated protein 1 (BAP1) gene and other genes are predisposed to developing cancers, prevalently mesothelioma. Their risk of developing mesothelioma further increases upon exposure to asbestos. Recent studies have revealed the mechanisms and the role of inflammation in asbestos carcinogenesis. Biomarkers for asbestos exposure and malignant mesothelioma have also been identified. These findings are leading to the development of novel therapeutic approaches to prevent or delay the growth of mesothelioma. Methods: Review of full length manuscripts published in English from January 1980 to February 2021 gathered from PubMed.gov from the National Center of Biotechnology Information and the National Library of Medicine were used to inform this review. Conclusions: Key regulators of chronic inflammation mediate asbestos-driven mesothelial cell transformation and survival through autophagic pathways. Recent studies have elucidated some of the key mechanisms involved in asbestos-induced chronic inflammation, which are largely driven by extracellular high mobility group box 1 (HMGB1). Upon asbestos exposure, mesothelial cells release HMGB1 from the nucleus to the cytoplasm and extracellular space, where HMGB1 initiates an inflammatory response. HMGB1 translocation and release also activates autophagy and other pro-survival mechanisms, which promotes mesothelioma development. HMGB1 is currently being investigated as a biomarker to detect asbestos exposure and to detect mesothelioma development in its early stage when therapy is more effective. In parallel, several approaches inhibiting HMGB1 activities have been studied and have shown promising results. Moreover, additional cytokines, such as IL-1β and TNF-α are being targeted to interfere with the inflammatory process that drives mesothelioma growth. Developing early detection methods and novel therapeutic strategies is crucial to prolong overall survival of patients with mesothelioma. Novel therapies targeting regulators of asbestos-induced inflammation to reduce mesothelioma growth may lead to clinical advancements to benefit patients with mesothelioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/pcm-21-12

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Key signaling pathways in asbestos-induced chronic inflammation and mesothelioma pathogenesis as well as related therapeutic approaches. Asbestos fibers cause necrotic mesothelial cell death and the consequent release of HMGB1 into the extracellular space. Extracellular HMGB1 initiates inflammatory response. It induces the accumulation of immune cells, as well as activates the NLRP3 inflammasome and NF-κB pathway, which causes secretion of many pro-inflammatory cytokines, including TNF-α and IL-1β. These factors bind to their respective receptors on neighboring mesothelial cells and promote the survival and transformation of mesothelial cells. Moreover, HMGB1 also induces autophagy in mesothelial cells following asbestos exposure that further promotes the cell survival and malignant transformation. The accumulation of survived mesothelial cells carrying DNA defects induced by asbestos and asbestos-generated ROS and RNS eventually leads to mesothelioma development. Many potential targets have been identified to interfere with the above carcinogenic process. For example, HMGB1 antagonist BoxA, anti-HMGB1 and anti-RAGE monoclonal antibodies can efficiently inhibit HMGB1 activities; Ethyl pyruvate reduces HMGB1 translocation and release by down-regulating the HMGB1-RAGE axis; IL-1 receptor antagonist Anakinra prevents the activity of IL-1β; and anti-inflammatory drug aspirin was also found to have anti-HMGB1 function. Created with Biorender.com.
Figure 1 Key signaling pathways in asbestos-induced chronic inflammation and mesothelioma pathogenesis as well as related therapeutic approaches. Asbestos fibers cause necrotic mesothelial cell death and the consequent release of HMGB1 into the extracellular space. Extracellular HMGB1 initiates inflammatory response. It induces the accumulation of immune cells, as well as activates the NLRP3 inflammasome and NF-κB pathway, which causes secretion of many pro-inflammatory cytokines, including TNF-α and IL-1β. These factors bind to their respective receptors on neighboring mesothelial cells and promote the survival and transformation of mesothelial cells. Moreover, HMGB1 also induces autophagy in mesothelial cells following asbestos exposure that further promotes the cell survival and malignant transformation. The accumulation of survived mesothelial cells carrying DNA defects induced by asbestos and asbestos-generated ROS and RNS eventually leads to mesothelioma development. Many potential targets have been identified to interfere with the above carcinogenic process. For example, HMGB1 antagonist BoxA, anti-HMGB1 and anti-RAGE monoclonal antibodies can efficiently inhibit HMGB1 activities; Ethyl pyruvate reduces HMGB1 translocation and release by down-regulating the HMGB1-RAGE axis; IL-1 receptor antagonist Anakinra prevents the activity of IL-1β; and anti-inflammatory drug aspirin was also found to have anti-HMGB1 function. Created with Biorender.com.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 107 references

Research works printed but not linked: 1

  1. [80]Jube SL, Rivera Z, Casalgrandi M, BoxA and ethyl pyruvate offer novel therapeutic approaches for human malignant mesothelioma. Cancer Res 2013; 73: 5557.

Cited by

See all 42

Metadata

Authors
Zolondick, A. A., Gaudino, G., Xue, J., Pass, H. I., Carbone, M., & Yang, H.
Affiliations
  • University of Hawaiʻi at Mānoa (US)
  • University of Hawaii Cancer Center (US)
  • NYU Langone Health (US)
Corresponding author
Yang, Haining
Venue
Precision Cancer Medicine
Published
2021-09
Volume
4
Pages
27-27
ISSN
2617-2216 (ISSN-L)
OpenAlex
W3191102673
Cited by
41
References
107
Citations by year
2026: 4 · 2025: 16 · 2024: 7 · 2023: 9 · 2022: 5
FWCI
0.84
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Precision Cancer Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
Funders
  • National Institutes of Health (5r01ca237235-05)
  • National Cancer Institute (R01CA160715, U01CA214195, R01 CA237235)
  • National Institute of Environmental Health Sciences (R01ES030948)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
  • Social Sciences › Health › Occupational Health and Global Justice
Keywords
malignant pleural mesothelioma, asbestos exposure, asbestos carcinogenesis, chronic inflammation, autophagy, HMGB1, BAP1 mutation, IL-1β, TNF-α, anti-inflammatory therapy, early detection, therapeutic target, occupational exposure, mineral fibers, cancer susceptibility

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches—a narrative review. https://app.cochat.ai/papers/10.21037/pcm-21-12
The paper
Zolondick, A. A., Gaudino, G., Xue, J., Pass, H. I., Carbone, M., & Yang, H. (2021). Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches—a narrative review. Precision Cancer Medicine. https://doi.org/10.21037/pcm-21-12

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.